Autologous stem cells cut insulin requirements in T2DM

07/1/2013 | Medical News Today

A study in Cell Transplantation found type 2 diabetes patients who received autologous bone marrow stem cells required lower insulin doses compared with those in the control group. Longer-duration studies with a larger number of participants will be needed to establish the efficacy of stem cell treatment in diabetes, researchers said.

View Full Article in:

Medical News Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC